Openbookopenbook
Equity
GIFLF
+0.0 · +0.00%
USD · PINK

Grifols S.A(GIFLF) Stock Analysis | Healthcare

USD --+0.00%
Reward60Moderate
Risk58Medium-High
75%Data
Value Trap
Market Cap:7.19Bn
ⓘ
Reward Rating
60
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
58
Medium-High
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GIFLF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for GIFLF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Grifols S.A?

, together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.

GIFLF · Verdict

Solid reward · elevated risk

GIFLF stands out on valuation and cash flow, but watch the balance sheet signal.

Based on 88% data coverage

GIFLF · Verdict

What’s working & what to watch

Strengths 3

  • Valuation81/100

    P/E 11.9× · PEG 0.26

  • Cash flow74/100

    10% free-cash-flow margin

  • Growth69/100

    Rev +7.4% CAGR · earnings +24.5%

Watchouts 3

  • Balance sheet29/100

    Net debt/EBITDA 7.1×

  • Volatility35/100

    Below average

  • Profitability38/100

    5% net margin · 6% ROE

Model-based scoring. For information only — not financial advice.

What is Grifols S.A?

, together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 7.19B, and a P/E ratio of 15.3x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

OPHLYMid Cap / 8B market cap
Ono Pharmaceutical Co Ltd
Compare
OGNMid Cap / 3.6B market cap
Organon & Co
Compare
SNPHYMid Cap / 3.6B market cap
Santen Pharmaceutical Co
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap7.19B
P/E Ratio15.3188
Dividend YieldN/A
Beta1.205
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.